Efficacy of salvage chemotherapy with ICE regimen in 52 patients with recurrent and refractory diffuse large B-cell lymphoma and its prognostic factors / 肿瘤

ABSTRACT

Objective: To investigate the efficacy and safety of salvage chemotherapy with ICE regimen (ifosfamide, etoposide and carboplatin) in patients with recurrent and refractory diffuse large B-cell lymphoma (DLBCL) and the related prognostic factors. Methods: The efficacy and side effects of salvage chemotherapy with ICE regimen in 52 patients with recurrent and refractory DLBCL were evaluated. The survival analysis was performed. The univariate and multivariate analyses were used to examine the related prodnostic factors. Results: The objective response rate (ORR) was 61.5% (32/52). The gender, age at diagnosis, extranodal involvement (≤1 vs>1), tumor cell origin [germinal-center B-cell-like (GCB) vs non-GCB] and B symptom were not associated with response to salvage chemotherapy with ICE regimen (all P>0.05). The patients with Ki-67≥75% had better response than those with Ki-670.05). The result of multivariate analysis showed that extranodal involvement and tumor cell origin were independent prognostic factors of PFS (both P0.05). The major side effect induced by ICE regimen was myelosuppression (80.8%), including grade 3/4 myelosuppression accounted for 55.8%. Conclusion: In patients with recurrent and refractory DLBCL, ICE can serve as an effective salvage chemotherapy regimen. The extranodal involvement and tumor cell origin were independent prognostic factors.